Through an agreement with National Health Service (NHS) and Sobi,( Swedish Orphan Biovitrium) people living with haemophilia A in the United Kingdom will have increased access to Elocta… read more.
Data from the Phase III REACH2 study published in The New England Journal of Medicine show Jakavi (ruxolitinib) improves outcomes across a range of efficacy measures in patients… read more.
Data from the Phase III REACH2 study published in The New England Journal of Medicine show Jakavi (ruxolitinib) improves outcomes across a range of efficacy measures in patients… read more.
Many of the 4,000 delegates at IMW in Boston this year, such as Professor Mohamad Mohty (Paris, France) highlighted the spirit of collaboration, with locals Professor Paul Richardson and Professor Noopur Raje discussing their highlights… read more.
In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients, the panel staked out their positions at the International… read more.
Article written by Tom Collins. Interview by Esther Drain.
Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing that could provide even more options, said Professor Philippe Moreau, head of the haematology department at University Hospital in Nantes, France.
Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.
Article written by Tom Collins. Interview by Esther Drain In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients,… read more.
Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing… read more.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the lessons that… read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Among the clinical studies that reported results at the EHA congress 2019 was part 1 of the CASSIOPEIA study…. read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Another study with significant practice implications is the COLUMBA study, presented by Professor Maria-Victoria Mateos (University Hospital of Salamanca, Spain). This… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
